Cytomegalovirus infection

1. Introduction

Cytomegalovirus (CMV), also known as human herpesvirus 5 (HHV-5), is a large double-stranded DNA virus belonging to the Herpesviridae family. It is one of the most common human pathogens worldwide, with seroprevalence ranging from 40% to nearly 100% depending on geography, socioeconomic status, and age. While CMV infection is typically asymptomatic or mild in immunocompetent hosts, it represents a major opportunistic pathogen in immunocompromised patients, such as transplant recipients, individuals with advanced HIV/AIDS, and patients receiving chemotherapy.

Perhaps most concerning, CMV is the leading infectious cause of congenital malformations worldwide, responsible for long-term sequelae such as sensorineural hearing loss, intellectual disability, developmental delay, and microcephaly.

The global medical significance of CMV stems from three main clinical scenarios:

1. Primary infection in immunocompetent individuals, usually subclinical but sometimes resembling infectious mononucleosis.

2. Congenital and perinatal infection, which may cause permanent neurological impairment.

3. Reactivation or reinfection in immunocompromised hosts, resulting in life-threatening end-organ disease (retinitis, colitis, pneumonitis, hepatitis, encephalitis).

In this review, we will explore CMV in detail, including virology, pathogenesis, immune evasion strategies, epidemiology, clinical manifestations, diagnostic approaches, therapeutic options, preventive strategies, and emerging research directions.

---

2. Virology and Structure

2.1 Taxonomy

• Family: Herpesviridae

• Subfamily: Betaherpesvirinae

• Genus: Cytomegalovirus

• Species: Human herpesvirus 5 (HHV-5)

Other members of the Betaherpesvirinae include human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7). Together, they share the ability to establish latency in leukocytes and to cause disease primarily in immunocompromised hosts.

2.2 Structure

CMV is one of the largest human viruses, with a genome of approximately 230 kilobases encoding more than 200 proteins. The virion is composed of:

• Nucleocapsid: Icosahedral, housing the double-stranded DNA genome.

• Tegument: Protein-rich layer surrounding the capsid, containing regulatory proteins essential for early infection stages.

• Envelope: Lipid bilayer derived from host membranes, studded with glycoproteins (gB, gH/gL complexes, gM/gN) necessary for attachment and entry.

2.3 Replication cycle

Like all herpesviruses, CMV follows a lytic and latent cycle:

1. Entry: Glycoproteins mediate fusion with host cell membranes (fibroblasts, epithelial cells, endothelial cells, leukocytes).

2. Immediate early (IE) gene expression: Regulates host immune evasion and prepares the cell for viral replication.

3. Early gene expression: Initiates DNA replication.

4. Late gene expression: Produces structural proteins for virion assembly.

5. Assembly and egress: Virions are assembled in the nucleus, trafficked through the cytoplasm, and released via exocytosis.

6. Latency: Established in myeloid lineage cells (monocytes, CD34+ progenitors). Reactivation occurs with immunosuppression.

2.4 Cytopathic effect

CMV causes cytomegaly—infected cells enlarge, with distinctive “owl’s eye” intranuclear inclusions, which are diagnostic on histology.

---

3. Epidemiology

3.1 Global distribution

• In high-income countries, 40–60% of adults are CMV-seropositive.

• In low- and middle-income countries, prevalence exceeds 90–95%.

• Infection is acquired earlier in childhood in resource-limited settings.

3.2 Transmission routes

• Congenital: Transplacental infection from a mother with primary infection or reactivation.

• Perinatal: Breast milk, vaginal secretions at birth.

• Horizontal: Saliva, urine, sexual contact.

• Iatrogenic: Blood transfusions, organ transplantation, hematopoietic stem cell transplantation.

3.3 Risk populations

• Pregnant women (risk of congenital CMV).

• Immunocompromised hosts (transplant patients, HIV/AIDS).

• Neonates (especially preterm infants).

3.4 Disease burden

• Congenital CMV occurs in 0.5–2% of live births worldwide, with 10–15% of infected infants developing permanent sequelae.

• In solid organ transplant recipients, CMV is the most common viral complication, with incidence rates of 20–60% without prophylaxis.

• Among HIV patients before ART, up to 40% developed CMV retinitis; incidence has declined in the ART era but persists in resource-limited settings.

---

4. Pathogenesis and Immune Evasion

4.1 Primary infection

• Often asymptomatic in immunocompetent hosts.

• Virus spreads via mucosal epithelium to lymph nodes and bloodstream.

• Monocytes and dendritic cells act as vehicles for dissemination.

4.2 Latency

• CMV persists in hematopoietic progenitor cells.

• Latency involves silencing of lytic genes and expression of latency-associated transcripts.

• Reactivation is triggered by inflammation, immunosuppression, or differentiation of monocytes into macrophages.

4.3 Immune evasion strategies

CMV has evolved numerous mechanisms to counteract host defenses:

• MHC class I downregulation: Viral proteins (US2, US3, US6, US11) interfere with antigen presentation.

• NK cell evasion: CMV expresses decoy MHC molecules (UL18) to inhibit NK activation.

• Cytokine modulation: CMV encodes viral IL-10 homolog (cmvIL-10) to suppress immune responses.

• Chemokine mimics: Modulate leukocyte trafficking.

• Blocking apoptosis: Viral proteins prevent programmed cell death to prolong infection.

---

5. Host Immune Response

5.1 Innate immunity

• NK cells play a critical role, especially early in infection.

• Interferons (IFN-α, IFN-β) limit viral replication.

• Dendritic cells detect viral components via pattern recognition receptors.

5.2 Adaptive immunity

• CD8+ T cells: Crucial for controlling viral replication.

• CD4+ T cells: Provide help for CD8+ cells and B cells.

• B cells/antibodies: Important for limiting dissemination but less effective in controlling established infection.

5.3 Immune control vs pathology

In immunocompetent hosts, robust immune responses suppress viral replication, but in immunosuppressed patients, insufficient immunity leads to unchecked viral spread and organ damage.

---

6. Clinical Manifestations

6.1 Immunocompetent hosts

• Most infections are silent.

• Symptomatic cases: CMV mononucleosis (fever, lymphadenopathy, atypical lymphocytosis, hepatosplenomegaly). Distinguishable from EBV mononucleosis by heterophile-negative Monospot test.

6.2 Immunocompromised hosts

• Solid organ transplant: CMV syndrome (fever, malaise, leukopenia) or tissue-invasive disease (colitis, hepatitis, pneumonitis).

• Hematopoietic stem cell transplant: CMV pneumonia, often fatal without treatment.

• HIV/AIDS: CMV retinitis (“pizza pie” retinal lesions with hemorrhage), colitis, esophagitis, encephalitis.

6.3 Congenital CMV

• Occurs when maternal primary infection or reactivation crosses the placenta.

• Symptomatic at birth (10–15%): Microcephaly, periventricular calcifications, hepatosplenomegaly, jaundice, petechiae (“blueberry muffin baby”), chorioretinitis, growth restriction.

• Long-term sequelae: Sensorineural hearing loss (most common), developmental delay, seizures, motor impairment.

6.4 Perinatal CMV

• Acquired during delivery or breastfeeding.

• Usually mild or asymptomatic, but may cause disease in preterm infants.

---

7. Diagnosis

7.1 Laboratory methods

• Serology:

  • CMV IgM = acute/recent infection.

  • CMV IgG = prior infection; rising titers suggest recent infection.

  • IgG avidity testing distinguishes primary from past infection.

• Molecular tests:

  • Quantitative PCR: Standard for diagnosis and monitoring viral load.

  • Detects active replication, used in transplant surveillance.

• Antigenemia assay:

  • pp65 antigen detection in leukocytes.

• Histopathology:

  • “Owl’s eye” intranuclear inclusions.

7.2 Imaging

• Congenital CMV: Ultrasound (microcephaly, calcifications, ventriculomegaly), MRI.

• Retinitis: Fundoscopy shows hemorrhagic necrosis (“pizza pie retina”).

---

8. Treatment

8.1 First-line antivirals

• Ganciclovir (IV): Nucleoside analog; bone marrow suppression common.

• Valganciclovir (oral): Prodrug, good bioavailability, used for prophylaxis and treatment.

8.2 Alternatives

• Foscarnet: Effective against resistant CMV; nephrotoxicity and electrolyte disturbances.

• Cidofovir: Used rarely; nephrotoxic.

• Letermovir: Newer antiviral targeting the terminase complex; approved for prophylaxis in stem cell transplant patients.

8.3 Adjunctive strategies

• Reduce immunosuppressive therapy if feasible.

• Intravenous immunoglobulin (IVIG) sometimes used in severe congenital or transplant cases.

---

9. Prevention

• In transplant patients:

  • Universal prophylaxis (valganciclovir, letermovir).

  • Preemptive therapy based on PCR monitoring.

• In pregnancy:

  • No vaccine yet.

  • Preventive counseling: hand hygiene, especially around young children.

  • Experimental use of CMV hyperimmune globulin (not standard).

• In blood/organ donation:

  • CMV-seronegative blood for at-risk recipients.

  • Leukoreduction reduces CMV transmission.

---

10. Resistance Mechanisms

• UL97 gene mutations → ganciclovir resistance.

• UL54 gene mutations → DNA polymerase resistance (foscarnet, cidofovir cross-resistance possible).

• Clinical management requires sequencing of resistant strains to guide therapy.

---

11. Current Research and Future Directions

• Vaccines: Subunit vaccines (glycoprotein B), DNA vaccines, mRNA vaccines (inspired by COVID-19 advances).

• Adoptive immunotherapy: Transfer of CMV-specific T cells in transplant patients.

• Novel antivirals: Maribavir (UL97 kinase inhibitor), terminase inhibitors.

• Immunomodulation: Blocking viral IL-10 homologs to restore host immunity.

---

12. Conclusion

Cytomegalovirus is a pervasive pathogen that exemplifies the dual nature of herpesviruses: silent coexistence in most individuals, yet devastating illness in vulnerable populations. It remains a leading cause of congenital malformations and a critical threat in transplant medicine and HIV/AIDS.

Although current antivirals and monitoring strategies have improved outcomes, challenges remain: drug resistance, toxicity, and lack of a licensed vaccine. Advances in molecular diagnostics, immunotherapy, and vaccine development promise a future where CMV’s burden may be dramatically reduced. Until then, vigilant surveillance, timely treatment, and global awareness remain our strongest defenses.